
9.30am EDT09:30
The EU has cancelled its annual reception at this year’s UN climate talks because of Covid restrictions, but a spokesperson denied that delegates would be banned from attending social events at the Glasgow conference.
The European Commission usually sends a delegation to UN climate talks to represent its 27 member states, but this year fewer top officials will attend.
A commission spokesperson denied reports that officials would be banned from socialising or attending side events at Cop26 over Covid concerns. They said:
The officials attending the conference will adhere to the sanitary restrictions and the safety measures which are put in place by the Cop presidency and the UNFCCC and of course we have full confidence in those.
The spokesperson said the EU would not be organising its usual annual reception due to Covid restrictions, but senior representatives had scheduled multiple bilateral meetings, adding:
We will be taking part in various events as usual so there is really no question of our diplomatic efforts being curbed in any way by the current situation.
In the UK, 328,287 people have tested positive for coronavirus from 18-24 October, an increase of 9,4% on the previous week. During the same period 949 people died within 28 days of a positive coronavirus test, an increase of 11.4%
Updated
at 9.37am EDT
8.50am EDT08:50
A bit more on that story about Merck asking for EU approval for its anti-coronavirus pill.
The US pharma company Merck has asked the European Medicines Agency to authorise its Covid-19 antiviral treatment, the first pill that has been shown to treat the disease.
The company said the EU drug regulator had started an expedited licensing process for molnupiravir, which forces coronavirus to mutate itself to death. If given the green light, it would be the first treatment for Covid-19 that does not need to be administered via needles or intravenous infusions.
Earlier this month, Merck asked the US regulator, the Food and Drug Administration, to approve molnupiravir, and a decision is expected within weeks.
The company reported this month that the pill cut hospitalisations and deaths by half among patients with early symptoms of Covid-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.
An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak healthcare systems.
It would also bolster a two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
Updated
at 9.22am EDT
5.47am EDT05:47
IOC issues Covid protocol plans for 2022 Beijing Winter Olympics and Paralympics
Updated
at 6.19am EDT